Atea Pharmaceuticals, Inc.·4

Jun 23, 5:00 PM ET

Adams Jerome M. 4

Research Summary

AI-generated summary

Updated

Atea (AVIR) Director Jerome M. Adams Exercises Options, Receives RSUs

What Happened

  • Director Jerome M. Adams reported derivative activity and awards on June 18, 2026. The Form 4 shows an exercise/conversion of 29,600 derivative shares (code M) and the acquisition of two awards totaling 64,400 restricted stock units (26,700 and 37,700 shares) (code A). All transactions were reported at $0 per share on the filing.

Key Details

  • Transaction date: June 18, 2026; filing date: June 23, 2026 (appears filed one business day late relative to the two-business-day Form 4 deadline).
  • Reported amounts and prices: 29,600 shares exercised/converted (M) at $0; RSU awards of 26,700 and 37,700 shares (A) at $0. No cash amounts are shown on the filing.
  • Shares owned after the transactions: not specified in the provided summary — see the full Form 4 for total holdings.
  • Footnotes of note:
    • F1: Each RSU represents a contingent right to one share of common stock.
    • F2: Some RSUs vested in full on June 18, 2026.
    • F3: Other RSUs vest in a single installment on the earlier of the next annual meeting after June 18, 2026 or June 18, 2027, subject to continued service.
    • F4: The option referenced vests in 12 monthly installments after June 18, 2026 and fully vests June 18, 2027, subject to continued service.
  • Transaction codes: M = exercise/conversion of a derivative; A = grant/award.

Context

  • These transactions represent awards and derivative activity (vesting/convertibility) rather than open-market purchases or sales. The $0 per-share reporting is typical for grants, vesting RSUs, or certain conversions/net settlements and does not indicate proceeds from a market sale. Because a Form 4 was filed after the two-business-day window, the filing is late by one business day; late filings reduce timely transparency but do not by themselves indicate any trading impropriety.